Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

F. Palandri, G.A. Palumbo, E. Abruzzese, A. Iurlo, N. Polverelli, E. Elli, M. Bonifacio, M. Bergamaschi, B. Martino, M. Tiribelli, G. Benevolo, A. Tieghi, N. Sgherza, A. Isidori, G. Binotto, M. Crugnola, F. Heidel, F. Cavazzini, C. Bosi, G. AuteriD. Cattaneo, R. Foà, R.M. Lemoli, A. Cuneo, M. Krampera, D. Bartoletti, M. Cavo, N. Vianelli, M. Breccia, R. Latagliata

Research output: Contribution to journalArticle

Abstract

The 2016 WHO criteria identified early primary myelofibrosis (PMF) as an individual entity with milder clinical features and better outcome compared with overt PMF. Here, we compared early and overt PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response, and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of hematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts. The application of 2016 WHO criteria is crucial to identify those PMF patients who deserve a stricter monitoring during treatment. © 2019 John Wiley & Sons, Ltd.
Original languageEnglish
Pages (from-to)418-423
Number of pages6
JournalHematological Oncology
Volume37
Issue number4
DOIs
Publication statusPublished - Oct 1 2019

Keywords

  • EARLY PMF
  • MYELOFIBROSIS
  • OVERT PMF
  • RUXOLITINIB
  • hemoglobin
  • ruxolitinib
  • antineoplastic agent
  • JAK2 protein, human
  • Janus kinase 2
  • protein kinase inhibitor
  • pyrazole derivative
  • tumor protein
  • adolescent
  • adult
  • aged
  • anemia
  • Article
  • bleeding
  • blood toxicity
  • bone marrow biopsy
  • cancer specific survival
  • clinical feature
  • clinical laboratory
  • clinical outcome
  • cohort analysis
  • female
  • heart disease
  • histology
  • human
  • infection
  • major clinical study
  • male
  • median survival time
  • myelofibrosis
  • myeloid metaplasia
  • overall survival
  • platelet count
  • priority journal
  • second cancer
  • splenomegaly
  • thrombocytopenia
  • treatment response
  • comparative study
  • differential diagnosis
  • early diagnosis
  • genetics
  • laboratory technique
  • middle aged
  • molecularly targeted therapy
  • organ size
  • pathology
  • retrospective study
  • spleen
  • thrombocythemia
  • treatment outcome
  • very elderly
  • World Health Organization
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Clinical Laboratory Techniques
  • Diagnosis, Differential
  • Early Diagnosis
  • Female
  • Humans
  • Janus Kinase 2
  • Male
  • Middle Aged
  • Molecular Targeted Therapy
  • Neoplasm Proteins
  • Organ Size
  • Primary Myelofibrosis
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Retrospective Studies
  • Spleen
  • Thrombocythemia, Essential
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib'. Together they form a unique fingerprint.

  • Cite this

    Palandri, F., Palumbo, G. A., Abruzzese, E., Iurlo, A., Polverelli, N., Elli, E., Bonifacio, M., Bergamaschi, M., Martino, B., Tiribelli, M., Benevolo, G., Tieghi, A., Sgherza, N., Isidori, A., Binotto, G., Crugnola, M., Heidel, F., Cavazzini, F., Bosi, C., ... Latagliata, R. (2019). Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Hematological Oncology, 37(4), 418-423. https://doi.org/10.1002/hon.2619